课题基金 / 基金详情

INTERLEUKIN 1 REDUCES GLYCOLYTIC UTILIZATION OF GLUCOSE BY PANCREATIC ISLETS

INTERLEUKIN 1 REDUCES GLYCOLYTIC UTILIZATION OF GLUCOSE BY PANCREATIC ISLETS
白细胞介素 1 减少胰岛对葡萄糖的糖酵解利用
批准号:
6118558
负责人:
ZHONGMIN ALEX MA
金额:
$0.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 1999-07-31

项目摘要

项目成果

ZHONGMIN ALEX MA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Culture of rat pancreatic islets with interleukin-1 (IL-1) results in up-regulation of the inducible isoform of nitric oxide synthase (iNOS) and overproduction of nitric oxide (NO). This is associated with reversible inhibition of both glucose-induced insulin secretion and islet glucose oxidation, and these effects are prevented by the iNOS inhibitor NG-monomethyl-arginine (NMMA). IL-1 also induces accumulation of nonesterified arachidonic acid in islets by an NO-dependent mechanism, as demonstrated by isotope dilution mass spectrometry and one potential explanation for that effect would involve an IL-1-induced enhancement of islet glycolytic flux. We have therefore examined effects of IL-1 on islet glycolytic utilization of glucose and find that culture of islets with IL-1 in medium containing 5.5 mM glucose results in suppression of islet glucose utilization subsequently measured at glucose concentrations between 6 and 18 mM. The IL-1-induced suppression of islet gluc ose utilization is associated with a decline in islet glucokinase mRNA content, as determined by competitive RT-PCR, and in glucokinase protein synthesis, as determined by immuno-precipitation experiments, and all of these effects are prevented by NMMA. These findings suggest that IL-1 can down-regulate islet glucokinase, which is the primary component of the islet glucose-sensor apparatus, by an NO-dependent mechanism. Because reductions in islet glucokinase levels are known to cause a form of type II diabetes mellitus, these observations raise the possibility that factors which increase islet NO levels might contribute to development of glucose intolerance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of DT-110 as an oral therapeutic for type 2 diabetes
  • 批准号:
    9046798
  • 项目类别:
  • 资助金额:
    $76.59万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
Development of DT-109 as an oral therapeutic for type 2 diabetes
  • 批准号:
    8830889
  • 项目类别:
  • 资助金额:
    $22.5万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
Development of DT-110 as an oral therapeutic for type 2 diabetes
  • 批准号:
    9146926
  • 项目类别:
  • 资助金额:
    $72.49万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
PROTECTION OF PANCREATIC BETA-CELLS BY GROUP VIA PHOSPHOLIPASE A(2)
  • 批准号:
    8361459
  • 项目类别:
  • 资助金额:
    $0.83万
  • 财政年份:
    2011
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
海外基金